Home Page > The Company > Investors
Shareholders
With a wealth of technological expertise and supported by strong financial partners, Biom'Up's development strategy consists of three main aims:
- To bring its proprietary ranges to market quickly
- To develop new medical devices targeting major surgical and regenerative medicine markets
- To reach new heights in our R&D, commercial, clinical and regulatory activities
Aquasourca is an investment company founded with private funds (€125M provided at the start) based in Lyon and Luxembourg. We invest between €3 and €10M per operation in profitable mature companies across a variety of business sectors (industry, services, healthcare, etc.) for capital operations (development capital, LBO, replacement capital, etc.). Our portfolio includes approximately forty lines of investment.
Mérieux Développement is a Mérieux Institute investment company, a French industrial group holding that specialises in the healthcare field, with currently close to 10,000 employees around the world through its subsidiaries bioMérieux (NYSE Euronext, BIM), Silliker, Transgene (NYSE Euronext, TNG) and ABL. Mérieux Développement hopes to invest €70M between 2010 and 2013 in the Healthcare sector, in support of dynamic entrepreneurs and companies whose products and services represent real advances for the improvement of patients' health throughout the world.
Created in 1927, Sham is a mutual insurance company that specialises in the management of risks taken by the players in the health and medico-social fields. Sham is the first insurer with civil responsibility for medical liabilities in France. It has 5,947 members - individuals and corporate bodies - and manages €1.4M worth of assets. Through its global risk management approach, Sham offers its members ranges of insurance and services that are completely adapted to their needs and specific requirements. Sham employs 270 people and in 2010 had a turnover of more than €290M. Since 2007, Sham has been investing in dynamic businesses in the healthcare industry.
For over 30 years now the Sofimac Partners group has been specialising in the fields of investment in non-listed companies in the South East of France. With a critical mass of assets worth €200M, Sofimac Partners manage a portfolio of approximately one hundred lines and investments totalling approximately €10M per year through different investment mediums. Its activities are structured around a capital-development/LBO in industry and services, and a technological centre that mainly targets the healthcare/biotechnology fields. In 2008 it raised funds to support young biomedical technology businesses located in the Rhône-Alpes valley/Northern Italy region.